2022
Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer
Unlu S, Kim JW. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer. Current Oncology Reports 2022, 24: 1619-1631. PMID: 35931885, DOI: 10.1007/s11912-022-01305-0.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine DiphosphateAntineoplastic AgentsClinical Trials, Phase II as TopicHumansMalePoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesProstatic Neoplasms, Castration-ResistantReceptors, AndrogenRiboseConceptsPARP inhibitorsBRCA2 mutationsProstate cancerFDA approvalMetastatic prostate cancer patientsAccelerated FDA approvalDeleterious BRCA2 mutationsHRR gene mutationsObjective response ratePhase II studyMetastatic prostate cancerProstate cancer patientsPoly (ADP-ribose) polymerase (PARP) inhibitorsUS FDA approvalSomatic mutationsMCRPC patientsCombination regimenII studyClinical benefitRadium-223Cancer patientsStandard treatmentAndrogen receptorDNA damage repair pathwaysClinical development
2011
Initial PSA Oscillations Precede Prolonged Stable Disease in a Patient Treated With a Therapeutic Cancer Vaccine
Kim JW, Madan RA, Gulley JL. Initial PSA Oscillations Precede Prolonged Stable Disease in a Patient Treated With a Therapeutic Cancer Vaccine. Clinical Genitourinary Cancer 2011, 10: 43-46. PMID: 22019260, PMCID: PMC3279569, DOI: 10.1016/j.clgc.2011.09.003.Peer-Reviewed Original ResearchMeSH KeywordsCancer VaccinesClinical Trials, Phase II as TopicHumansMaleMiddle AgedPrognosisProstate-Specific AntigenProstatic Neoplasms